Paul Kolodzik returns to The AGEIST Podcast to discuss his pioneering work around GLP-1s: using these medications to help people reduce their alcohol intake
Glossary CLBP chronic low back pain CKD chronic kidney disease CNS central nervous system CV cardiovascular CVD cardiovascular disease FDA Food and Drug Administration GLP-1 glucagon-like peptide-1 GLP-1s glucagon-like peptide-1 receptor agonists HF heart failure HTN hypertension MACE major adverse cardiovascular events MASH metabolic dysfunction-associated steatohepatitis OA osteoarthritis OSA obstructive sleep apnea PAD peripheral arterial disease SC subcutaneous SGLT2i sodium-glucose co-transporter 2 inhibitor sNDA supplemental New Drug Application T1DM type 1 diabetes mellitus T2DM type 2 diabetes mellitus U.S
We can guide you through every step of your weight loss journey, providing tailored diet and exercise plans
Though these drugs have been prescribed for people with diabetes for decades, the conversation around their use for weight loss has exploded in the past couple of years
Semaglutide is the name on everybody's lips these days, as a stunningly effective treatment for type 2 diabetes and as a surprisingly effective and low side-effect weight loss medication
In preclinical studies using rodent models, tri agonist peptides similar to Retatrutide have been associated with coordinated changes in biomarkers linked to energy metabolism, lipid handling, and endocrine signaling[5]